Lactobacillus reuteri ： Bloating and Intestinal Gas
B エビデンス 少なくとも1件のランダム化試験がこれを支持しており、おおむね一貫した結果が得られています。Multiple RCTs in breastfed infants show reduced crying time (50-70 min/day reduction). Well-established evidence for infantile colic but limited to infant population.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dreuteri\u0026condition\u003Dbloating\u002Dand\u002Dgas';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
結論
Multiple RCTs in breastfed infants show reduced crying time (50-70 min/day reduction). Well-established evidence for infantile colic but limited to infant population.
Key Study Findings
basic science
Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA.
Dose: Lactobacillus reuteri E9 (dose not specified)
vs: Placebo
効果: None
< 0.05
Observational Study
n=65
Open-label
Incidence and Characterization of SIBO in NAFLD Patients.
Dose: None
vs: None
Outcome: SIBO prevalence in NAFLD patients
効果: SIBO in 37%; post-treatment 4% remained+
None
対象集団: Adults with NAFLD diagnosed via FibroScan
Randomized Controlled Trial
n=56
15 weeks
Double-blind
Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and …
Dose: 4x10^8 CFU (induction), 2x10^8 CFU (standard)
vs: Placebo
Outcome: Constipation symptoms and QoL (Constipaq/CSS)
効果: None
pP0.05
対象集団: Adults with functional constipation
Other
n=54
Double-blind
Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, …
Dose: None
vs: Simethicone
Outcome: Safety and efficacy for functional bloating
効果: None
pP0.008
対象集団: Adults with functional bloating
Meta-Analysis
n=3122
Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a …
Dose: None
vs: Triple therapy alone/placebo
Outcome: H. pylori eradication rate and side effects
効果: None
None
対象集団: Children with H. pylori infection
Randomized Controlled Trial
n=101
16 weeks
Double-blind
Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, …
Dose: L. reuteri DSM 17938 (1e8 CFU twice daily)
vs: placebo
Outcome: abdominal pain severity (Wong-Baker FACES)
効果: None
None
対象集団: Children aged 6-15 with functional abdominal pain
Key Statistics
7
研究数
500
参加者数
↑
Positive
B
グレード
Referenced Papers
Frontiers in bioscience …
2025
Euroasian journal of …
2025
Beneficial microbes
2018
35 件の引用
Translational gastroenterology and …
2018
24 件の引用
European journal of …
2017
93 件の引用
The Journal of …
2016
84 件の引用
Middle East journal …
2013
13 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 100 million - 5 billion CFU/day
- infantilecolic:
- 100 million CFU/day (DSM 17938 strain, 5 drops)
- adultgisupport:
- 1-5 billion CFU/day
上限量： Well-tolerated up to 10 billion CFU/day in clinical trials
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| Lactobacillus reuteri E9 (dose not specified) | -- | Positive | -- |
| None | -- | Positive | 65 |
| 4x10^8 CFU (induction), 2x10^8 CFU (standard) | 15 weeks | Positive | 56 |
| None | -- | Positive | 54 |
| None | -- | Positive | 3122 |
| L. reuteri DSM 17938 (1e8 CFU twice daily) | 16 weeks | Positive | 101 |
| None | 4 weeks | Positive | -- |
推奨摂取タイミング： Before meals or on empty stomach; for infants, add drops to breast milk or formula
Safety & Side Effects
報告されている副作用
- ⚠ Mild gas in initial days of use
- ⚠ Occasional increased fussiness in infants during adjustment (transient)
- ⚠ Rare loose stools
- ⚠ Very rare: bacteremia in immunocompromised individuals
既知の相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
- ● Proton pump inhibitors (altered gastric pH may affect colonization)
耐容上限摂取量： Well-tolerated up to 10 billion CFU/day in clinical trials
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Lactobacillus reuteri help with Bloating and Intestinal Gas?
Based on 7 studies with 500 participants, there is moderate evidence from clinical studies that Lactobacillus reuteri may support Bloating and Intestinal Gas management. Our evidence grade is B (Good Evidence).
How much Lactobacillus reuteri should I take for Bloating and Intestinal Gas?
Studies have used various dosages. A commonly studied range is 100 million - 5 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus reuteri?
Reported side effects may include Mild gas in initial days of use, Occasional increased fussiness in infants during adjustment (transient), Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus reuteri and Bloating and Intestinal Gas?
We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 500 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Bloating and Intestinal Gas
Lactobacillus reuteri 他の症状・状態について
References
- [1] Yongcheng Jiang et al.. Front Biosci (Landmark Ed). 2025. Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA. doi:10.31083/FBL39587 PubMed
- [2] Shamim Naizr et al.. Euroasian J Hepatogastroenterol. 2025. Incidence and Characterization of SIBO in NAFLD Patients. doi:10.5005/jp-journals-10018-1468 PubMed
- [3] G Riezzo et al.. Benef Microbes. 2018. Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and bowel habit in functional constipation. doi:10.3920/BM2017.0049 PubMed
- [4] Ovidiu Burta et al.. Transl Gastroenterol Hepatol. 2018. Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, randomised, double-blind, parallel group, clinical … doi:10.21037/tgh.2018.09.11 PubMed
- [5] Jue-Rong Feng et al.. Eur J Clin Pharmacol. 2017. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. doi:10.1007/s00228-017-2291-6 PubMed
- [6] Zvi Weizman et al.. J Pediatr. 2016. Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial. doi:10.1016/j.jpeds.2016.04.003 PubMed
- [7] Behnaz Amirimani et al.. Middle East J Dig Dis. 2013. Probiotic vs. Placebo in Irritable Bowel Syndrome:A Randomized Controlled Trial. PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。